Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
¿Qué tal es el rendimiento del precio de la acción Novo Nordisk A/S?
El precio actual de Novo Nordisk A/S es de $36.5, ha aumentado un 0.44% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Novo Nordisk A/S?
Novo Nordisk A/S pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Novo Nordisk A/S?
La capitalización bursátil actual de Novo Nordisk A/S es $123.0B
¿Es Novo Nordisk A/S una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 28 analistas han realizado calificaciones de análisis para Novo Nordisk A/S, incluyendo 4 fuerte compra, 11 compra, 14 mantener, 0 venta, y 4 fuerte venta